CoChat
Sign Up
Cited by 17

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Herbal and dietary supplement-induced liver injury in Taiwan: comparison with conventional drug-induced liver injury

Huang, Yi-Shin, Chang, Ting-Tsung, Peng, Cheng-Yuan, Lo, Gin-Ho, Hsu, Chao-Wei, Hu, Chi-Tan, Huang, Yi-Hsiang·2021·Hepatology International
DOI 10.1007/s12072-021-10241-3
Open this paper in CoChat — free account

Abstract

Background and aims Whether herbal and dietary supplements (HDS) are safer than Western conventional drugs is controversial. The aim of this study was to explore the characteristics and risk factors for HDS-induced liver injury (HILI) in Taiwan. Methods This is a 9-year multi-center prospective study conducted in Taiwan from 2011 to 2019. Patients with HILI were compared to those with conventional drug-induced liver injury (CILI). Results A total of 1,297 patients were enrolled, of whom 285 (22.0%) had HILI and 1,012 (78.0%) had CILI. Compared to the CILI group, the HILI group had higher initial serum alanine aminotransferase, alkaline phosphatase (ALP), peak ALP and bilirubin levels, and higher rates of jaundice, ascites, encephalopathy, coagulopathy, sepsis and acute liver failure. In addition, the HILI group had a higher mortality rate than the CILI group (12.6 vs. 8.0%, p = 0.016). Hepatitis B carrier status, elevated baseline liver biochemical tests and the use of crude herbs (without processing) were associated with an increased risk of HILI-related mortality (adjusted hazard ratios [95% confidence intervals]: 2.90 [1.43-5.99], 2.40 [1.01-5.68] and 2.94 [1.45-5.97], respectively). Conclusions HDS are popular and incriminated in more than one-fifth of drug-induced liver injuries in Taiwan. The patients with HILI were more severe than those with CILI in terms of liver biochemical tests, complications and mortality. Hepatitis B carriers, those with elevated baseline liver…

Overview

Integrity signals

Registry

Crossref · 10.1007/s12072-021-10241-3

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In China, the proportion of HMs as cause of DILI has been reported to be approximately 20-30%.

    “In China, this proportion has been reported to be approximately 20-30% [118-120].”

    From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [120]

  • Multiple studies from Asia, Europe, and Latin-America have shown that liver injury caused by HMs/HDS is more severe than that caused by other drugs, with a higher risk of death or requirement of liver transplantation.

    “Multiple studies from Asia, Europe, and Latin-America have shown that liver injury caused by HMs/HDS is more severe than that caused by other drugs, with a higher risk of death or requirement of liver transplantation [120,124,134].”

    From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [120]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 28

  1. Devarbhavi H, Choudhury AK, Sharma MK, APASL ACLF working party, et al. Drug-induced acute-on-chronic liver failure in Asian patients. Am J Gastroenterol 2019;114:929–937 · DOI · Paper page
  2. Devarbhavi H, Patil M, Reddy VV, et al. Drug-induced acute liver failure in children and adults: results of a single-centre study of 128 patients. Liver Int 2018;38:1322–1329 · DOI
  3. Navarro VJ, Lucena MI. Hepatotoxicity induced by herbal and dietary supplements. Semin Liver Dis 2014;34:172–193 · DOI
  4. Seeff LB, Bonkovsky HL, Navarro VJ, et al. Herbal products and the liver: a review of adverse effects and mechanisms. Gastroenterology 2015;148:517–532 · DOI
  5. Teschke R, Andrade RJ. Drug, herb, and dietary supplement hepatotoxicity. Int J Mol Sci 2016;17(9):1488 · DOI · Paper page
  6. Navarro VJ, Khan I, Björnsson E, et al. Liver injury from herbal and dietary supplements. Hepatology 2017;65:363–373 · DOI
  7. Teschke R, Danan G. Worldwide use of RUCAM for causality assessment in 81,856 idiosyncratic DILI and 14,029 HILI cases published 1993-Mid 2020: a comprehensive analysis. Medicines (Basel) 2020;79(10):62 · DOI
  8. Jing J, Teschke R. Traditional Chinese medicine and herb-induced liver injury: comparison with drug-induced liver injury. J Clin Transl Hepatol 2018;6:57–68 · DOI
  9. Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology 2015;148:1340–1352 · DOI · Paper page
  10. Chih LH, On AWF, Huang YS. Correlation of anti-tuberculosis drug-related liver injury and liver function monitoring: a 12 years’ experience in Taiwan Drug Relieve Foundation. J Food Drug Anal 2014;22:356–362 · DOI
  11. Fontana RJ, Watkins PB, Bonkovsky HL, DILIN Study Group. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf 2009;32:55–68 · DOI · Paper page
  12. Danan G, Benichou C. Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meeting: application to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323–1330 · DOI · Paper page
  13. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67:328–357 · DOI · Paper page
  14. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43:1317–1325 · DOI · Paper page
  15. Wendon J, Cordoba J, Dhawan A, et al. EASL clinical practical guidelines on the management of acute (fulminant) liver failure. J Hepatol 2017;66:1047–1081 · DOI · Paper page
  16. Arroyo V, Moreau R, Jalan R, EASL-CLIF Consortium CANONIC Study, et al. Acute-on-chronic liver failure: a new syndrome that will re-classify cirrhosis. J Hepatol 2015;62(1 Suppl):S131−S143 · DOI
  17. Medina-Caliz I, Garcia-Cortes M, Gonzalez-Jimenez A, et al. Herbal and dietary supplement-induced liver injuries in the Spanish DILI Registry. Clin Gastroenterol Hepatol 2018;16:1495–1502 · DOI · Paper page
  18. Stephens C, Robles-Diaz M, Medina-Caliz I, et al. Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry. J Hepatol 2021;75:86–97 · DOI · Paper page
  19. Bessone F, García-Cortés M, Medina-Caliz I, et al. Herbal and dietary supplements-induced liver injury in Latin America: Experience from the Latindili Network. Clin Gastroenterol Hepatol 2021. (Epub ahead of print) · DOI · Paper page
  20. Devarbhavi H, Joseph T, Sunil Kumar N, The Indian Network of Drug-Induced Liver Injury, et al. Etiology, clinical features, outcome and prognostic markers in 1288 patients. J Clin Exp Hepatol 2021;11:288–298 · DOI · Paper page
  21. Suk KT, Kim DJ, Kim CH, et al. A prospective nationwide study of drug-induced liver injury in Korea. Am J Gastroenterol 2012;107:1380–1387 · DOI · Paper page
  22. Radimer K, Bindewald B, Hughes J, et al. Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999–2000. Am J Epidemiol 2004;160:339–349 · DOI
  23. Wong WM, Wu PC, Yuen MF, et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 2000;31:201–206 · DOI
  24. Wang NT, Huang YS, Lin MH, et al. Chronic hepatitis B infection and risk of anti-tuberculosis drug-induced liver injury: systematic review and meta-analysis. J Chin Med Assoc 2016;79:368–374 · DOI
  25. Philips CA, Paramaguru R, Joy AK, et al. Clinical outcomes, histopathological patterns, and chemical analysis of Ayurveda and herbal medicine associated with severe liver injury—a single-center experience from southern India. Indian J Gastroenterol 2018;37:9–17 · DOI · Paper page
  26. Philips CA, Paramaguru R, Augustine P, et al. A single-center experience on outcomes of complementary and alternative medicine use among patients with cirrhosis. Hepatol Commun 2019;3:1001–1012 · DOI · Paper page
  27. Sarin SK, Choudhury A, Sharma MK, APASL ACLF Research Consortium (AARC) for APASL ACLF working Party, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int 2019;13:353–390 · DOI
  28. Davern TJ, Chalasani N, Fontana RJ, Drug-Induced Liver Injury Network (DILIN), et al. Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology 2011;141:1665–1672 · DOI

Cited by

Sorted by citations

Metadata

Authors
Huang, Y.-S., Chang, T.-T., Peng, C.-Y., Lo, G.-H., Hsu, C.-W., Hu, C.-T., & Huang, Y.-H.
Venue
Hepatology International
Publisher
Springer Science and Business Media LLC
Published
2021-08-11
Volume
15
Issue
6
Pages
1456-1465
ISSN
  • 1936-0533
  • 1936-0541
DOI
10.1007/s12072-021-10241-3
Cited by
17
References
4
Language
en
Licence
Funders
Food and Drug Administration (DOH100-99TFDA-P-092, DOH101-FDA-41103)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review